Citation Impact
Citing Papers
On‐treatment prediction of sustained response to peginterferon alfa‐2a for HB eAg‐negative chronic hepatitis B patients
2014
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B
2012
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
2015 StandoutNatureNobel
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
2005 Standout
EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
2019
Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B
2014
Management of hepatitis B
2007
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
2012
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
2015
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Human Epidermal Growth Factor Receptor 2 Testing in Primary Breast Cancer in the Era of Standardized Testing: A Canadian Prospective Study
2014
Gastric cancer
2016 Standout
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Cancer Statistics, 2021
2021 Standout
A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C
2003 Standout
Optimal chemotherapy for advanced gastric cancer: is there a global consensus?
2013
Treatment predictors of a sustained virologic response in hepatitis B and C
2008
Interleukin‐29 uses a type 1 interferon‐like program to promote antiviral responses in human hepatocytes†
2006
Cisplatin or Not in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
2013
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
Interferons at age 50: past, current and future impact on biomedicine
2007
A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B
2014
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B
2008
A robust cell culture system supporting the complete life cycle of hepatitis B virus
2017 StandoutNobel
Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection
2016
The biology and management of non-small cell lung cancer
2018 StandoutNature
Hepatitis B: Reflections on the current approach to antiviral therapy
2008
Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures
2010 StandoutNobel
Gastric cancer—molecular and clinical dimensions
2013
Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited
2009
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Hepatitis B Virus Infection
2008
Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells
2010 StandoutNobel
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab
2011
New insight in the pathobiology of hepatitis B virus infection
2012
Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update*
2003
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
2008
Antiviral drug-resistant HBV
2007
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up
2006
Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a
2012
Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)
2014
Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
2016
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective
2010
Hepatitis B virus infection
2009 Standout
The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal of a new TSNM staging system
2017
The role of quantitative hepatitis B surface antigen revisited
2016
Pharmacology and therapeutic potential of interferons
2012
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
2006
Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype
2013
Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent
2015
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
2004 Standout
Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B
2009
Hepatitis B vaccines
2003
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
The RNA Sensor RIG-I Dually Functions as an Innate Sensor and Direct Antiviral Factor for Hepatitis B Virus
2014 StandoutNobel
Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants
2012
The landscape of long noncoding RNAs in the human transcriptome
2015 Standout
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
2005
Lung cancer: current therapies and new targeted treatments
2016 Standout
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016
Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses
2008
Overview of hepatitis B viral replication and genetic variability
2016
Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa
2009
Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy
2005
Mechanisms of Hepatic Fibrogenesis
2008 Standout
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
2006 Standout
Chronic hepatitis B
2007 Standout
Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B
2007
Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta
2011
Chronic hepatitis B: Update 2009 #
2009 Standout
Updated Clinical Classification of Pulmonary Hypertension
2013 Standout
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
2006
Optimal management of hepatitis B virus infection – EASL Special Conference
2015
Clinical uses of interferons
2007
IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage
2013 StandoutNobel
Comparison of the Efficacy of Lamivudine Plus Adefovir Versus Entecavir in the Treatment of Lamivudine-Resistant Chronic Hepatitis B: A Systematic Review and Meta-Analysis
2013
Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines
2013
Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report
2011
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
2020 Standout
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection
2008
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
2015 StandoutNobel
Hepatitis B virus infection
2018
Gastric cancer
2020 Standout
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
Response-Guided Peginterferon Therapy in Hepatitis B E Antigen-Positive Chronic Hepatitis B Using Serum Hepatitis B Surface Antigen Levels
2013
Protective and pathogenic functions of macrophage subsets
2011 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies
2007
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
2015
Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
2005
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
2006
Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B
2005
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA
2016 StandoutNobel
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen–negative patients with chronic hepatitis B
2012
Interferon-inducible antiviral effectors
2008 Standout
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Hepatocellular Carcinoma
2019 Standout
Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial
2019
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
AASLD guidelines for treatment of chronic hepatitis B
2015
Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection
2008
Baseline HBsAg and HBcrAg titres allow peginterferon‐based ‘precision medicine’ in HBeAg‐negative chronic hepatitis B patients
2016
Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems
2014 StandoutNobel
Present and future therapies of hepatitis B: From discovery to cure
2015
Chemotherapy for advanced gastric cancer
2017 Standout
Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection
2016
Short-Term Lamivudine Therapy in Hbeag-Negative Chronic Active Hepatitis B in Taiwan
2006
Screening for Hepatitis C Virus Infection in Adolescents and Adults
2020
Hepatitis B Virus Replication and Liver Disease Progression: The Impact of Antiviral Therapy
2006
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis
2015
Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues
2012
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study
2011
Works of Peter Button being referenced
Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program
2012
Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
2009
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
2012 Standout
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
2004
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
2008
Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B
2008
Aspiration: First-Line Erlotinib (E) Until and Beyond Recist Progression (Pd) in Asian Patients (Pts) with Egfr Mutation-Positive (Mut+) Nsclc
2014
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer
2015